Welcome to our dedicated page for Horizon Space Acquisition II SEC filings (Ticker: HSPTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Horizon Space Acquisition II's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Horizon Space Acquisition II's regulatory disclosures and financial reporting.
Horizon Space Acquisition II Corp. reported a small net loss of $29,122 for the quarter ended March 31, 2026, as interest income of $588,076 on its Trust investments was more than offset by formation and operating costs of $364,905 and interest expense of $252,293.
The SPAC redeemed 3,219,311 ordinary shares for $34,221,276, reducing the Trust Account to $39,390,860 and leaving a working capital deficit of $1,784,554. It continues to pursue the SL Bio business combination, supported by a $7,800,000 PIPE and multiple extension deposits, but management discloses substantial doubt about the company’s ability to continue as a going concern if a deal is not completed by the current deadline.
Horizon Space Acquisition II Corp. reported a small net loss of $29,122 for the quarter ended March 31, 2026, as interest income of $588,076 on its Trust investments was more than offset by formation and operating costs of $364,905 and interest expense of $252,293.
The SPAC redeemed 3,219,311 ordinary shares for $34,221,276, reducing the Trust Account to $39,390,860 and leaving a working capital deficit of $1,784,554. It continues to pursue the SL Bio business combination, supported by a $7,800,000 PIPE and multiple extension deposits, but management discloses substantial doubt about the company’s ability to continue as a going concern if a deal is not completed by the current deadline.
Horizon Space Acquisition II Corp. notified the SEC it will file its quarterly report on Form 10-Q late for the period ended March 31, 2026 under Rule 12b-25. The company expects a significant change in its results for the quarter due to extension-fee deposits totaling $790,000 and a shareholder redemption payment of $34,221,276 related to 3,219,311 ordinary shares redeemed on March 17, 2026. The registrant states it intends to file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
Horizon Space Acquisition II Corp. notified the SEC it will file its quarterly report on Form 10-Q late for the period ended March 31, 2026 under Rule 12b-25. The company expects a significant change in its results for the quarter due to extension-fee deposits totaling $790,000 and a shareholder redemption payment of $34,221,276 related to 3,219,311 ordinary shares redeemed on March 17, 2026. The registrant states it intends to file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
Horizon Space Acquisition II Corp. received an amended Schedule 13G/A filing by Mizuho Financial Group, Inc. stating that Mizuho (through its subsidiaries) reports 0 shares beneficially owned of Horizon Space Acquisition II Corp. common stock (CUSIP G4627B103), representing 0.0% of the class. The filing identifies Mizuho Securities USA LLC as the subsidiary holding any underlying position and includes the parent certification regarding comparable foreign regulatory scheme. The signature on the amendment is dated 05/14/2026.
Horizon Space Acquisition II Corp. received an amended Schedule 13G/A filing by Mizuho Financial Group, Inc. stating that Mizuho (through its subsidiaries) reports 0 shares beneficially owned of Horizon Space Acquisition II Corp. common stock (CUSIP G4627B103), representing 0.0% of the class. The filing identifies Mizuho Securities USA LLC as the subsidiary holding any underlying position and includes the parent certification regarding comparable foreign regulatory scheme. The signature on the amendment is dated 05/14/2026.
Horizon Space Acquisition II Corp. extended the deadline to complete its initial business combination by one month, from April 18, 2026 to May 18, 2026. This is the third of up to twelve one‑month extensions allowed under its charter amendment.
The sponsor deposited a $50,000 extension fee into the company’s trust account and received an unsecured promissory note for the same amount. The note bears no interest and is due at the business combination or the company’s expiry, and may be converted into private units at $10.00 per unit.
Horizon Space Acquisition II Corp. extended the deadline to complete its initial business combination by one month, from April 18, 2026 to May 18, 2026. This is the third of up to twelve one‑month extensions allowed under its charter amendment.
The sponsor deposited a $50,000 extension fee into the company’s trust account and received an unsecured promissory note for the same amount. The note bears no interest and is due at the business combination or the company’s expiry, and may be converted into private units at $10.00 per unit.
Horizon Space Acquisition II Corp. files its annual report outlining progress toward a merger and liquidity risks. The SPAC completed a $69,000,000 IPO and over-allotment in November 2024, placing the proceeds in a Nasdaq-listed trust structure. It entered a Business Combination Agreement with SL Bio Ltd., creating PubCo, whose ordinary shares are expected to trade on Nasdaq after closing. Shareholders approved the SL Bio deal and related governance changes, but 3,502,404 shares were submitted for redemption and a further 3,219,311 were redeemed at a later extension vote, sharply shrinking the public float. The company arranged a $7,800,000 PIPE for PubCo and multiple trust extensions funded via promissory notes. For 2025 it reported net income of $1,809,006, driven by $2,889,530 of trust interest, but year-end cash outside the trust was only $7,917 with a working capital deficit of $1,319,649, and management cites substantial doubt about continuing as a going concern without completing a business combination or obtaining further financing.
Horizon Space Acquisition II Corp. files its annual report outlining progress toward a merger and liquidity risks. The SPAC completed a $69,000,000 IPO and over-allotment in November 2024, placing the proceeds in a Nasdaq-listed trust structure. It entered a Business Combination Agreement with SL Bio Ltd., creating PubCo, whose ordinary shares are expected to trade on Nasdaq after closing. Shareholders approved the SL Bio deal and related governance changes, but 3,502,404 shares were submitted for redemption and a further 3,219,311 were redeemed at a later extension vote, sharply shrinking the public float. The company arranged a $7,800,000 PIPE for PubCo and multiple trust extensions funded via promissory notes. For 2025 it reported net income of $1,809,006, driven by $2,889,530 of trust interest, but year-end cash outside the trust was only $7,917 with a working capital deficit of $1,319,649, and management cites substantial doubt about continuing as a going concern without completing a business combination or obtaining further financing.
Horizon Space Acquisition II Corp. outlines a PIPE financing to support its proposed business combination with SL BIO Ltd. and PubCo. PubCo has entered subscription agreements with PIPE investors to purchase an aggregate 780,000 PubCo units at $10.00 per unit, for expected gross proceeds of about $7,800,000 at the business combination closing.
Each unit includes one PubCo ordinary share and one series A preferred share that converts into one-third of a PubCo ordinary share six months after closing. PubCo will file a resale registration statement for the ordinary and conversion shares, and PIPE investors have agreed to a six‑month lock-up after the PIPE closing, subject to customary exceptions and to the business combination closing.
Horizon Space Acquisition II Corp. outlines a PIPE financing to support its proposed business combination with SL BIO Ltd. and PubCo. PubCo has entered subscription agreements with PIPE investors to purchase an aggregate 780,000 PubCo units at $10.00 per unit, for expected gross proceeds of about $7,800,000 at the business combination closing.
Each unit includes one PubCo ordinary share and one series A preferred share that converts into one-third of a PubCo ordinary share six months after closing. PubCo will file a resale registration statement for the ordinary and conversion shares, and PIPE investors have agreed to a six‑month lock-up after the PIPE closing, subject to customary exceptions and to the business combination closing.
Horizon Space Acquisition II Corp. entered into a new unsecured promissory note for $50,000 with William Wang to fund an extension fee, allowing its initial business combination deadline to move from March 18, 2026 to April 18, 2026. This is the second of up to twelve one‑month extensions permitted under its charter amendment, which can push the deadline to February 18, 2027.
The note bears no interest and is due upon either completion of the business combination or the company’s expiry date. William Wang, Chief Executive Officer of SL BIO Ltd., may elect to convert the $50,000 note into Horizon Space private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one‑tenth of an ordinary share.
Horizon Space Acquisition II Corp. entered into a new unsecured promissory note for $50,000 with William Wang to fund an extension fee, allowing its initial business combination deadline to move from March 18, 2026 to April 18, 2026. This is the second of up to twelve one‑month extensions permitted under its charter amendment, which can push the deadline to February 18, 2027.
The note bears no interest and is due upon either completion of the business combination or the company’s expiry date. William Wang, Chief Executive Officer of SL BIO Ltd., may elect to convert the $50,000 note into Horizon Space private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one‑tenth of an ordinary share.
Wolverine Asset Management, Wolverine Holdings, Christopher L. Gust, and Robert R. Bellick filed Amendment No. 1 to a Schedule 13G/A reporting their relationship to Horizon Space Acquisition II Corp. The filing states each filer has 0% beneficial ownership and no sole or shared voting or dispositive power over the issuer's ordinary shares. The cover shows 02/24/2026; signatures are dated 02/27/2026. The issuer's principal executive office address is listed as 1412 Broadway, 21st Floor, Suite 21V, New York, NY 10018.
Wolverine Asset Management, Wolverine Holdings, Christopher L. Gust, and Robert R. Bellick filed Amendment No. 1 to a Schedule 13G/A reporting their relationship to Horizon Space Acquisition II Corp. The filing states each filer has 0% beneficial ownership and no sole or shared voting or dispositive power over the issuer's ordinary shares. The cover shows 02/24/2026; signatures are dated 02/27/2026. The issuer's principal executive office address is listed as 1412 Broadway, 21st Floor, Suite 21V, New York, NY 10018.
Horizon Space Acquisition II Corp. reports shareholder approvals that advance its planned merger with SL BIO Ltd. and extend its deadline to complete a business combination. Investors approved the business combination with SL Bio, related governance changes at PubCo, and the appointment of William Wang Ching-Dong as sole director effective at the first merger’s closing.
In a separate meeting, shareholders approved amendments to Horizon’s charter and trust agreement so the company can extend its February 18, 2026 termination date in up to twelve one‑month increments to February 18, 2027, funded by monthly deposits into the trust account of the lesser of $50,000 or $0.033 per remaining public share.
Horizon Space Acquisition II Corp. reports shareholder approvals that advance its planned merger with SL BIO Ltd. and extend its deadline to complete a business combination. Investors approved the business combination with SL Bio, related governance changes at PubCo, and the appointment of William Wang Ching-Dong as sole director effective at the first merger’s closing.
In a separate meeting, shareholders approved amendments to Horizon’s charter and trust agreement so the company can extend its February 18, 2026 termination date in up to twelve one‑month increments to February 18, 2027, funded by monthly deposits into the trust account of the lesser of $50,000 or $0.033 per remaining public share.
Horizon Space Acquisition II Corp. received an updated Schedule 13G/A (Amendment No. 3) from Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. stating that they now beneficially own 0 ordinary shares, representing 0% of the company’s ordinary shares.
The reporting entities disclose no sole or shared voting power and no sole or shared dispositive power over Horizon Space Acquisition II Corp. shares. They also indicate that they own 5 percent or less of the class, confirming that they are no longer significant shareholders and that any prior position has effectively been reduced to zero.
Horizon Space Acquisition II Corp. received an updated Schedule 13G/A (Amendment No. 3) from Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. stating that they now beneficially own 0 ordinary shares, representing 0% of the company’s ordinary shares.
The reporting entities disclose no sole or shared voting power and no sole or shared dispositive power over Horizon Space Acquisition II Corp. shares. They also indicate that they own 5 percent or less of the class, confirming that they are no longer significant shareholders and that any prior position has effectively been reduced to zero.